J Pediatr Intensive Care 2014; 03(01): 041-044
DOI: 10.3233/PIC-14079
Case Report
Georg Thieme Verlag KG Stuttgart – New York

Therapeutic plasma exchange in familial hemophagocytic lymphohistiocytosis

Alcia Edwards-Richards
a   Department of Pediatrics, Division of Pediatric Nephrology, University of Miami, Holtz Children's Hospital at Jackson Health System, Miami, FL, USA
b   Department of Pediatrics, Pediatric Postgraduate Training Program, University of Miami, Holtz Children's Hospital at Jackson Health System, Miami, FL, USA
,
Marissa Defreitas
a   Department of Pediatrics, Division of Pediatric Nephrology, University of Miami, Holtz Children's Hospital at Jackson Health System, Miami, FL, USA
b   Department of Pediatrics, Pediatric Postgraduate Training Program, University of Miami, Holtz Children's Hospital at Jackson Health System, Miami, FL, USA
,
Chryso Katsoufis
a   Department of Pediatrics, Division of Pediatric Nephrology, University of Miami, Holtz Children's Hospital at Jackson Health System, Miami, FL, USA
,
Asumthia Jeyapalan
c   Department of Pediatrics, Critical Care Medicine, University of Miami, Holtz Children's Hospital at Jackson Health System, Miami, FL, USA
,
Michael Nares
c   Department of Pediatrics, Critical Care Medicine, University of Miami, Holtz Children's Hospital at Jackson Health System, Miami, FL, USA
,
Carolyn L. Abitbol
a   Department of Pediatrics, Division of Pediatric Nephrology, University of Miami, Holtz Children's Hospital at Jackson Health System, Miami, FL, USA
› Author Affiliations

Subject Editor:
Further Information

Publication History

11 February 2014

28 April 2014

Publication Date:
28 July 2015 (online)

Abstract

Familial hemophagocytic lymphohistiocytosis is a rare, life-threatening disorder characterized by impaired cytotoxicity, hypercytokinemia and immune-mediated organ injury. We report a 7-week-old male of consanguineous parents who presented with fever, pancytopenia and multi-organ failure. Elevated inflammatory markers and hypercytokinemia led to the diagnosis of familial hemophagocytic lymphohistiocytosis, which was confirmed with genetic testing. With the fulminant multiorgan failure, therapeutic plasma exchange was instituted, using the Prismaflex® platform, followed by standard chemo-immunotherapy. There was dramatic reversal of the multi-organ failure and stabilization of the coagulopathy with this neo-adjuvant therapy. Thereafter, he was maintained in clinical remission with chemo-immunotherapy for 3 mo while awaiting stem cell transplantation.